22,304 reports of this reaction
2.9% of all DUPILUMAB reports
#7 most reported adverse reaction
ECZEMA is the #7 most commonly reported adverse reaction for DUPILUMAB, manufactured by sanofi-aventis U.S. LLC. There are 22,304 FDA adverse event reports linking DUPILUMAB to ECZEMA. This represents approximately 2.9% of all 782,562 adverse event reports for this drug.
Patients taking DUPILUMAB who experience eczema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ECZEMA is a less commonly reported adverse event for DUPILUMAB, but still significant enough to appear in the safety profile.
In addition to eczema, the following adverse reactions have been reported for DUPILUMAB:
The following drugs have also been linked to eczema in FDA adverse event reports:
ECZEMA has been reported as an adverse event in 22,304 FDA reports for DUPILUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ECZEMA accounts for approximately 2.9% of all adverse event reports for DUPILUMAB, making it a notable side effect.
If you experience eczema while taking DUPILUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.